June 2018, Series C
Metacrine is a San Diego based biotechnology company with exceptional chemistry capabilities and a potential best-in-class non-bile acid FXR agonist being studied for NASH and in various GI conditions. Investors include NEA, Arch, venBio, Polaris and Venrock.
March 2018, Series B
Orasis is a clinical-stage pharmaceutical company developing an innovative eye drop for the treatment of presbyopia symptoms as an alternative to reading glasses. Investors include Sequoia, Visionary Ventures and SBI (Japan).
March 2018, At-the-Market
Novus is a specialty pharma company focused on disorders of the near, nose and throat (ENT). Lead product OP-02 is a surfactant-based, combination drug product being developed for otitis media (middle ear inflammation). Venture investors include Orbimed, Peregrine and Pontifax.
November 2017, Series B
Allakos is developing AK002, a first-in-class antibody drug targeting Siglec-8 which is expressed on eosinophils and mast cells, for a variety of allergic, inflammatory and proliferative diseases. Investors include NEA, Redmile, Partner Fund, Rock Springs, Samsara, Alta Partners, RiverVest, Roche Ventures and 3X5 Partners.
November 2017, Series A
Biolinq is a digital health company with a wirelessly-enabled biosensor patch that is capable of continuously monitoring multiple biomarkers. Its lead application is a next-gen CGM (continuous glucose monitor) for diabetes patients. Investors include Merck KGaA, Hikma Pharmaceuticals, Grey Sky Ventures and Three Leaf Ventures.
September 2017, Series A
Engage is developing Staccato® Alprazolam, a small, easy-to-use hand-held drug-device combination product that leverages an FDA-approved delivery system with FDA-approved Alprazolam for the cessation of active and acute epileptic seizures. Investors include TPG, Adage Capital and Lumira Capital.
March 2017, Series B
January 2018, NASDAQ: RCKT
Rocket Pharma is developing a broad gene therapy portfolio for devastating rare diseases and has assembled an all-star scientific and management team. Lead program is a lentiviral vector for Fanconi Anemia. Investors include RTW Investments, Cormorant Asset Management and Tavistock.